Rie Sugimoto

Dr. Rie Sugimoto


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2023 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
RSRie Sugimoto
Rie Sugimoto
LLLingaku Lee
Lingaku Lee
YTYuki Tanaka
Yuki Tanaka
YMYusuke Morita
Yusuke Morita
MHMasayuki Hijioka
Masayuki Hijioka
MFMasayuki Furukawa
Masayuki Furukawa
Trace elements are minerals that are present in very low concentrations in the human body and yet are crucial for a wide range of physiological functions. Zinc, the second most abundant trace element, is obtained primarily from the diet. After being taken up in the intestine, zinc is distributed to various target organs, where it plays key roles in processes such as immunity, protein folding, apoptosis, and antioxidant activity. Given the important role of zinc in a wide range of enzymatic reactions and physiological processes, zinc deficiency has been identified in a variety of diseases, notably cancer. In recent years, multiple meta-analyses and reviews looking at zinc levels in individual cancer types have been published, as have a plethora of primary studies demonstrating a link between low zinc levels and specific types of cancer. In this review, we summarize recent evidence implicating low zinc concentrations in serum or tissues as a characteristic in a wide range of cancers. We also discuss preliminary findings indicating that zinc level measurement could ultimately become a useful clinical tool for cancer diagnosis and predicting outcomes in patients with cancer. Finally, we suggest future directions for further elucidating the role of zinc deficiency in cancer development and progression.

9 August 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
EOEiichi Ogawa
Eiichi Ogawa
MKMotoyuki Kohjima
Motoyuki Kohjima
TKToshimasa Koyanagi
Toshimasa Koyanagi
KDKazufumi Dohmen
Kazufumi Dohmen
AOAritsune Ooho
Aritsune Ooho
TGThe Kyushu University Liver Disease Study (KULDS) Group
The Kyushu University Liver Disease Study (KULDS) Group
Background and Aim: Long‐term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long‐term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited. This study aimed to evaluate the 5‐year virological effectiveness and renal safety of sequential TAF therapy, with a focus on those with pre‐existing CKD.Methods: This real‐world, multicenter, retrospective study included 414 CHB patients aged ≥ 18 years who switched from a prior NUC to TAF and were followed for at least 5 years. Patients were stratified based on renal function (CKD or non‐CKD) at baseline. Study endpoints included 5‐year virological efficacy, biochemical and fibrosis responses, and renal function changes.Results: Among the patients, 100 (24.2%) had CKD at the time of switching to TAF. Over 5 years, HBV DNA suppression rate increased from 85.0% to 100%, HBV DNA suppression with target not detected rate rose from 74.0% to 91.0%, and alanine aminotransferase normalization rate (AASLD criteria) improved from 66.0% to 79.0%, similar to the results of patients with non‐CKD. Estimated glomerular filtration rate remained stable regardless of baseline renal status or prior NUC regimen, demonstrating long‐term renal safety. There were no cases of HBV DNA breakthrough, including among those previously on combination NUCs. For patients with cirrhosis, the FIB‐4 index significantly improved over time (p = 0.008).Conclusions: Sequential TAF therapy demonstrated robust virological efficacy, biochemical and fibrosis improvements, and excellent renal safety over 5 years, irrespective of baseline renal function.

11 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EOEiichi Ogawa
Eiichi Ogawa
HNHideyuki Nomura
Hideyuki Nomura
MNMakoto Nakamuta
Makoto Nakamuta
NFNorihiro Furusyo
Norihiro Furusyo
EKEiji Kajiwara
Eiji Kajiwara
JHJun Hayashi
Jun Hayashi
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antivirals (DAAs). However, it remains unclear if DAAs themselves have an influence on or facilitate the development of HCC. This multicenter cohort study included CHC patients without a history of HCC who achieved HCV elimination by DAAs. Cohorts of 835 patients treated with a sofosbuvir (SOF)-based regimen and 835 treated with a SOF-free regimen were matched 1:1 by propensity scoring with nine variables to evaluate differences in HCC incidence. The median observation period was 3.5 years. Sixty-nine cases of HCC were found during 5483.9 person-years (PY) over the entire follow-up period. The annual incidence was similar for both groups (SOF-based 1.25 and SOF-free 1.27 per 100 PY, respectively: adjusted hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.75–2.12, p = 0.39). However, the annual incidence within the first two years was higher for patients treated with SOF than for those without, but did not reach significance (1.50 and 0.97 per 100 PY incidence rates, respectively: adjusted HR 2.05, 95% CI 0.98–4.25, p = 0.06). In summary, DAA treatment with SOF was not associated with an increase in the development of de novo HCC.

15 September 2022 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
TSTomonari Shimagaki
Tomonari Shimagaki
KSKeishi Sugimachi
Keishi Sugimachi
YMYohei Mano
Yohei Mano
EOEmi Onishi
Emi Onishi
YTYuki Tanaka
Yuki Tanaka
YTYasushi Toh
Yasushi Toh
Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare malignant mesenchymal tumor that usually occurs in children and is rarely diagnosed in adults. Case presentation: The case was a female in her late 20s who presented with a huge liver mass found upon the examination of fever. Imaging analysis showed a well-defined mass measuring 9 cm in the largest dimension in the right posterior segment of the liver. The patient underwent right hemi-hepatectomy. Histopathological studies revealed that the circumscribed tumor was composed of a proliferation of atypical epithelioid to spindle-shaped cells with pleomorphic nuclei arranged in haphazard pattern. Histopathological features observed in immunohistochemical analyses confirmed a final diagnosis of UESL. Genome analysis using FoundationOne CDx revealed 11 somatic mutations including TP53 (R196*) and STK11 (F354L). Adjuvant chemotherapy with ifosfamide and etoposide was performed, and the case has been followed up without recurrence for 1 year after hepatectomy. Conclusions: A UESL should be considered in the differential diagnosis of large and well-defined solid liver lesions. Although the prognosis of UESL is extremely unfavorable, aggressive surgical resection with adjuvant chemotherapy and genomic analysis may be helpful for ensuring long-term survival.

1 October 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YAYojiro Arinobu
Yojiro Arinobu
RSRie Sugimoto
Rie Sugimoto
MAMina Akaiwa
Mina Akaiwa
KAKazuhiko Arima
Kazuhiko Arima
TOTakeshi Otsuka
Takeshi Otsuka
KIKenji Izuhara
Kenji Izuhara

7 October 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
EOEiichi Ogawa
Eiichi Ogawa
AKAkira Kawano
Akira Kawano
AOAritsune Ooho
Aritsune Ooho
NFNorihiro Furusyo
Norihiro Furusyo
TSTakeaki Satoh
Takeaki Satoh
TGThe Kyushu University Liver Disease Study (KULDS) Group
The Kyushu University Liver Disease Study (KULDS) Group